OBJECTIVE： To observe therapeutic efficacy and safety of pidotimod combined with ceftriaxone sodium in the treatment of elderly bronchopneumonia. METHODS： A total of 164 elderly patients with bronchopneumonia were randomly divided into observation group （82 cases） and control group （82 cases）. Based on routine treatment， control group was given Ceftriaxone sodium for injection 2 g added into 0.9％ Sodium chloride solution 100 mL intravenously， once a day. Observation group was additionally given Pidotimod oral solution 7 mL， twice a day， on the basis of control group. Both group were treated for 2 weeks. Clinical efficacy， defervescence time， cough and wheezing disappearance time， chest radiograph improvement time and average hospitalization time were observed in 2 groups. The serum levels of TNF-α， IL-6， hs-CRP， IgG， IgA and IgM before and after treatment， the occurrence of ADR were observed. RESULTS： Total response rate of observation group （95.12％） was significantly higher than that of control group （81.71％）； and defervescence time， cough and wheezing disappearance time， chest radiograph improvement time and average hospitalization time were significantly shorter than control group， with statistical significance （P＜0.05）. After treatment， serum levels of TNF-α， IL-6， hs-CRP and IgM in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group； the levels of IgG and IgA in 2 groups were significantly higher than before treatment， and the observation group was significantly higher than the control group， with statistical significance（P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Pidotimod combined with ceftriaxone shows significant therapeutic efficacy for elderly bronchopneumonia and improve clinical symptoms without increasing the occurrence of ADR.